Entries |
Document | Title | Date |
20080234366 | PHARMACEUTICAL FORMULATION CONTAINING AN SGLT2 INHIBITOR - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 09-25-2008 |
20080234367 | Methods for Treating Obesity Employing an SGLT2 Inhibitor and Compositions Thereof - Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof. | 09-25-2008 |
20080249165 | Glycosides and Salts Thereof - The invention relates to new polysulfated glycosides of formula (I), the salts thereof formed with alkali metals or alkaline-earth metals, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. | 10-09-2008 |
20080287529 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME - The present invention relates to physical crystal structures of compound of the formula (I): | 11-20-2008 |
20080306144 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors - Method for the preparation of ester compounds for use as skin brightening agents and compositions for brightening skin containing the ester compounds. | 12-11-2008 |
20090048335 | PROCESS FOR PREPARING SIMVASTATIN - Preparation of simvastatin. | 02-19-2009 |
20090076134 | DEUTERIUM-ENRICHED SIMVASTATIN - The present application describes deuterium-enriched simvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090111869 | BENZOQUINONE ANSAMYCINS - The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions. | 04-30-2009 |
20090156667 | METHOD OF TREATING ASTHMA, ALLERGIC RHINITIS, AND SKIN DISORDERS - The use of 5,6,7-trihydroxyheptanoic acid and analogs is disclosed for the treatment of asthma, allergic rhinitis, and skin disorders such as allergic dermatitis, contact hypersensitivity, urticaria (hives), rosacea, or psoriasis. | 06-18-2009 |
20090186938 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS - Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus | 07-23-2009 |
20090197947 | MEDICAMENTS AND METHODS FOR LOWERING PLASMA LIPID LEVELS AND SCREENING DRUGS - The invention relates to compositions, medicaments, methods for treating individuals with high plasma lipid levels, and methods for screening drug candidates useful in, for example, the treatment of hypercholesterolemia. Specifically, the invention relates to the discovery that MTP inhibition leads to increased accumulation in cellular free-cholesterol and is useful in the development of compositions, medicaments, methods of treatment and drug screening methods to treat high plasma lipid levels. | 08-06-2009 |
20090215887 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS - Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions. | 08-27-2009 |
20090221698 | MANNOSE DERIVATIVES FOR KILLING TUMOR CELLS - A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or 2-FM or 2-CM. The killing is believed to be due to an interference with glycosylation. A theranostic method includes determining whether a patient. cancer tumor sample comprises cells sensitive to killing to at least one mannose analog due to an interference with glycosylation. | 09-03-2009 |
20090247623 | DERIVATIVES OF EPIRUBICIN, THEIR MEDICINAL APPLICATION AND PHARMACEUTICALY ACCEPTABLE FORMS OF DRUGS - The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV. | 10-01-2009 |
20090281175 | Avermectin compounds and treatment of dermatological disorders in humans therewith - Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 11-12-2009 |
20090286870 | Cancer Treatment Using FTS and 2-Deoxyglucose - Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed. | 11-19-2009 |
20090306199 | Method for inhibiting activation of macrophages, inhibiting formation of osteoclasts, inhibiting function of osteoclasts, and/or activating osteoblasts - A method for inhibiting the activation of macrophages, inhibiting the formation of osteoclasts, inhibiting the function of osteoclasts, and/or activating osteoblasts in a mammal is provided. The method comprises the administration of an effective amount of kinsenoside of formula (I) or a pharmaceutically acceptable salt or ester thereof to the mammal: | 12-10-2009 |
20090312410 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease, specifically MI and including early-onset MI, and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 12-17-2009 |
20090312411 | PREVENTING OR REDUCING RISK OF MISCARRIAGES - The present disclosure provides methods of reducing pregnancy loss or miscarriage in patients by administering compounds that inhibit tissue factor (TF) expression and/or activity on neutrophils and/or monocytes, such as for example, statins, and methods of diagnosing patients having an increased risk of miscarrying. | 12-17-2009 |
20090318547 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted difluorobenzyl-benzene derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders. | 12-24-2009 |
20090326057 | THERAPEUTIC USES OF UROLITHINS - The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject. | 12-31-2009 |
20100010080 | USE OF TYLVALOSIN AS ANTIVIRAL AGENT - The invention relates to the use of a macrolide antibiotic, tylvalosin, as an anti-viral agent. Tylvalosin is particularly useful for the treatment of PRRSV. | 01-14-2010 |
20100016422 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETR- AHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE - Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders. | 01-21-2010 |
20100029759 | COMPOSITION USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES - It is described the use of L-canitine and/or an alkanoyl L-canitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes. | 02-04-2010 |
20100048690 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS - Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus | 02-25-2010 |
20100048691 | COMPOSITION USEFUL FOR THE PREVENTION OF TYPE 2 DIABETES AND ITS COMPLICATIONS IN PRE-DIABETIC PATIENTS WITH INSULIN RESISTANCE - The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance. | 02-25-2010 |
20100063141 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition. | 03-11-2010 |
20100105768 | MOLD-INHIBITING METHOD AND COMPOSITION - Disclosed is a method for inhibiting the growth of mold on building materials by application onto and/or incorporation into the building material of a mold-inhibiting composition comprising dehydroacetic acid or a salt thereof and, optionally, an additional fungicidal agent such as a quaternary ammonium compound. A preferred application of the method is the inhibition of mold growth on plasterboard (drywall). | 04-29-2010 |
20100125102 | ESTROGENIC-ACTIVE COMPOUNDS AND APPLICATION THEREOF - The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ERβ and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms. | 05-20-2010 |
20100130600 | LIPOPROTEIN LIPASE AND ITS EFFECT ON STATIN TREATMENTS - The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus. | 05-27-2010 |
20100144862 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome. | 06-10-2010 |
20100216873 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors - Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions. | 08-26-2010 |
20100216874 | HYDROXYTYROSOL-RICH COMPOSITION FROM OLIVE VEGETATION WATER AND METHOD OF USE THEREOF - The invention provides olive-derived hydroxytyrosol. According to one aspect of the invention, vegetation water is collected from olives. Acid is added to stabilize the vegetation water and prevent fermentation. The mixture is incubated to allow oleuropein to convert to hydroxytyrosol, and then fractionated to separate hydroxytyrosol from other components. The hydroxytyrosol is useful as a therapeutic and anti-oxidant for a variety of health purposes, including for the treatment of skin damage. In addition, the hydroxytyrosol is useful as a natural anti-bacterial, anti-viral and fungicidal product for agricultural and pest control applications. | 08-26-2010 |
20100227919 | Dioxaspiroketal Derivatives, Process for Their Preparation and Uses Thereof - The invention relates to dioxaspiroketal derivatives of formula (I): wherein R, is selected from the group consisting of H, straight or branched chain C | 09-09-2010 |
20110009482 | METHODS OF TREATING COPD - Disclosed is a method of treating chronic obstructive disease, said method comprising administering an effective amount of a CXCR2 antagonist and administering an effective amount of at least one drug selected from the group consisting of: angiotensin-converting enzyme inhibitors, Angiotensin II receptor antagonists, cardioselective beta blockers, and lipid regulating drugs. Examples of the CXCR2 antagonist include: (formula 1.0A and 1.0B). | 01-13-2011 |
20110021623 | SYSTEM AND METHODS OF MELANOMA PREVENTION - Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to prevent damage and/or death of melanocytes. The inhibitor agent can be applied to the skin or ingested. | 01-27-2011 |
20110034549 | Antitumoral Compounds - A compound of general formula (I) | 02-10-2011 |
20110039925 | CYCLOBUTYL SULFONES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS - The invention encompasses a novel class of cyclobutyl sulfone derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included. | 02-17-2011 |
20110071219 | Hemostatic Effects of Glucono-Delta-Lactone - Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states. | 03-24-2011 |
20110082200 | 5,6,7-TRIHYDROXYHEPTANOIC ACID AND ANALOGS FOR THE TREATMENT OF OCULAR DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVE AND ANGIOGENIC RESPONSES - Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed. | 04-07-2011 |
20110112186 | DIAGNOSTIC METHODS - This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy. | 05-12-2011 |
20110124723 | Compounds for Preventing and Treating Plasmodium Infections - The present invention relates to the use of at least one compound of formula (I) for the manufacture of a medicament intended for preventing or treating infections by a | 05-26-2011 |
20110130450 | PRAVASTATIN EXTRACTION - The present invention provides a method for the purification of pravastatin comprising extracting a solution comprising pravastatin in a water-immiscible solvent with water at a pH value ranging from 5.0 to 7.0. | 06-02-2011 |
20110130451 | METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS - The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis. | 06-02-2011 |
20110144198 | BREAST CANCER PROGNOSTICS - The present invention provides new methods, uses and means for breast cancer prognostics. The provided method for establishing a prognosis for a mammalian subject having a breast cancer, comprises the steps of: obtaining a hormone receptor status of the subject; obtaining an HMGCR protein value of the subject; and correlating the hormone receptor status and the HMGCR protein of the subject to a prognosis for the subject. | 06-16-2011 |
20110178169 | USE OF 5-HYDROXY-2-HYDROXYMETHYL-Y-PYRONE (HMP) AS A LEISHMANICIDAL AGENT - The present invention refers to the use of HMP (a secondary metabolite obtained from | 07-21-2011 |
20110184056 | USE OF STATINS AS ANTICONVULSANTS, ANTIEPILEPTICS AND NEUROPROTECTORS - The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described. | 07-28-2011 |
20110184057 | PARENTERAL TREATMENT WITH STATINS - Cancer patients, patients with cognitive dysfunction, or patients with pulmonary hypertension are treated with parenterally administered therapeutic doses of statins. Particularly, transdermal, injection employing liquid infusion or particles are employed. For cancer, the statins may be used by themselves or in conjunction with a chemotherapeutic regimen. Liver cancer is treated orally with super doses of statins. | 07-28-2011 |
20110207809 | METHOD OF ACCELERATING CORNEAL WOUND HEALING - The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed. | 08-25-2011 |
20110230551 | WITHAFERIN A ANALOGS AND USES THEREOF - The present invention provides a novel class of withanolides that have been isolated from | 09-22-2011 |
20110237662 | Use of Statins to Inhibit Inflammation and Vascular Disease - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 09-29-2011 |
20110251275 | OMEGA-3 FATTY ACIDS FOR REDUCTION OF LP-PLA2 LEVELS - Methods are provided for utilizing omega-3 fatty acids, or a combination of a dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein-associated phospholipase A | 10-13-2011 |
20110269830 | STATIN NANOPARTICLES - The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilisate. The present invention also relates to a pharmaceutical composition including at least one complex and/or nanoparticles such as previously defined. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of hyperlipemia and hypercholesterolemia. | 11-03-2011 |
20110319484 | NEUROPROTECTIVE COMPOUNDS - The invention describes the use of (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl-1-naphthalenyl propanoate derivatives, optionally mono- or di-methylated at the carbon in the alpha position of propanoic acid, of formula (I), where R is CH | 12-29-2011 |
20120035256 | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease - The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments for mammals at risk of an ischemic event. | 02-09-2012 |
20120095091 | ANTIEPILEPTIC, HYPOCHOLESTEROLEMIC AND NEUROPROTECTIVE COMPOUND - The present invention describes a compound of formula (I) | 04-19-2012 |
20120172425 | RED YEAST RICE EXTRACT HIGH IN MONACOLIN K CONTENT - Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject. | 07-05-2012 |
20120196928 | RED YEAST RICE EXTRACT HIGH IN MONACOLIN K CONTENT - Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject. | 08-02-2012 |
20120202877 | ANTI-INFLUENZA AGENTS - The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents. | 08-09-2012 |
20120232136 | SUBSTANCE WITH SEDATIVE EFFECT - A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days. | 09-13-2012 |
20120252889 | POLYKETIDE MOLECULES AS ANTICANCER AGENTS - The present invention relates to a polyketide molecule of the following formula (I): | 10-04-2012 |
20120270933 | LIQUID STATIN FORMULATION - The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention. | 10-25-2012 |
20120283323 | Treating Learning Deficits with Inhibitors of HMG CoA Reductase - The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder. | 11-08-2012 |
20130197073 | HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND - The present invention describes a compound of formula (I) | 08-01-2013 |
20130225670 | Methods of Treating Asthma Using Statins - The present disclosure generally provides methods for assessing a subject's responsiveness to a statin therapy, and selection of a statin dose based upon such methods. The disclosure further provides methods for treating asthma by administering a statin therapy. | 08-29-2013 |
20130225671 | Methods of Treating Seizure Disorders - Seizure disorders are treated by Ras inhibitors. In an embodiment, the Ras inhibitor includes a farnesyl transferase inhibitor. In another embodiment, the farnesyl transferase inhibitor includes a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor. In another embodiment, the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor is not a Ras inhibitor. Subjects having fragile X syndrome, autism, Angelman syndrome, Costello syndrome, cardio facio cutaneous syndrome, neurofibromatosis type I, Noonan syndrome and Coffin-Lowry syndrome that have seizure disorders can be treated. | 08-29-2013 |
20130237595 | ANTIBACTERIAL AGENTS: HIGH-POTENCY MYXOPYRONIN DERIVATIVES - The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents. | 09-12-2013 |
20130261175 | 2-PYRONES - The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I). | 10-03-2013 |
20130267587 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN - Anhydrous topical gel composition of mupirocin or its salts comprising: a) a lipophilic base selected from the group consisting of petrolatum, medium-chain triglycerides, isopropyl myristate and mixtures thereof; b) a bioadhesive selected from the group comprising polyvinylpyrrolidone and polymethacrylates; and c) a solvent selected from the group comprising ethanol, propanol, and isopropanol; which is stable and shows an increased residence time of the active ingredient in the skin, resulting in an improved clinical effect in the treatment of bacterial skin infections while maintaining the safety profile of the commercial pharmaceutical product. | 10-10-2013 |
20130296421 | ARYLPROPIONYL-ALPHA-PYRONE ANTIBACTERIAL AGENTS - The invention provides a compound of formula (I): or a salt thereof, wherein R | 11-07-2013 |
20130303605 | EXTERNAL COMPOSITION FOR SKIN CONTAINING MANASSANTIN B AS ACTIVE INGREDIENT AND THE USE THEREOF FOR SKIN WHITENING - Disclosed herein are an external composition for skin, which contains, as an active ingredient, manassantin B extracted from | 11-14-2013 |
20130310450 | Compound Separated from Monascus-Fermented Rice,The Preparation Method and Uses Thereof - The present invention discloses a compound separated from | 11-21-2013 |
20140113962 | INHIBITORS OF NITRIC OXIDE SYNTHASE - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 04-24-2014 |
20140163097 | ANIMAL SUPPLEMENTS AND FOOD COMPOSITIONS CONTAINING SOLUBLE MONENSIN COMPOSITION, AND METHODS AND PROCESSES THEREFOR - The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin, a solvent, and a mineral mix, wherein the mineral mix is substantially free of monocalcium phosphate. In addition, the present disclosure provides processes of preparing animal feed supplements and animal food compositions comprising such animal feed supplements. The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin, a solvent, and an alkaline component. In addition, the present disclosure provides animal food compositions containing such animal feed supplements, and methods for their use. | 06-12-2014 |
20140171497 | ANIMAL SUPPLEMENTS AND COMPOSITIONS CONTAINING SOLUABLE MONENSIN AND METHODS THEREFOR - The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin and a solvent, wherein the supplement is a solution. The disclosure also provides food compositions comprising a therapeutically effective amount of monensin, a solvent, and an animal feed, methods of administering the food compositions, and processes for making the food compositions. | 06-19-2014 |
20140200269 | Combination of a Statin and a Taxane for the Treatment of Gastric Cancer - The present invention relates to a combination of (i) a statin, and (ii) a taxane, for simultaneous or sequential use in the treatment of a patient suffering from solid tumor, e.g. a gastric cancer. The present invention also provides a statin, for use in a method for enhancing sensitivity of a patient suffering from a solid tumor to a taxane. | 07-17-2014 |
20140309295 | ANTIEPILEPTIC, HYPOCHOLESTEROLEMIC AND NEUROPROTECTIVE COMPOUND - The present invention describes a compound of formula (I) | 10-16-2014 |
20140323561 | Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs - Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I). | 10-30-2014 |
20140336248 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further comprise identifying a subject having a disorder suitable for treatment with the aqueous compositions described, comprising detecting one or more biomarkers predictive of the prevalence of a cancer having or enriched for cancer stem cells (CSCs). | 11-13-2014 |
20140371305 | Mupirocin Antibiotic Composition - An antibiotic inhalation or irrigation composition for the treatment of bacterial infections especially in the respiratory tract, is provided. The antibiotic inhalation or irrigation composition may include a mixture of mupirocin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in an apparatus where a low-frequency acoustic field is applied to facilitate mixing. Antibiotic inhalation or irrigation composition may be obtained in powder or solution form. In other embodiments, antibiotic inhalation or irrigation composition may be employed to produce a topical formulation for the treatment of traumatic skin lesions. In some embodiments, other suitable poloxamers or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic inhalation or irrigation composition may provide improved solubility and bioavailability of mupirocin, thus decreasing side effects and time of treatment. | 12-18-2014 |
20150025134 | Compositions and Methods for the Treatment of Sleep Apnea - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 01-22-2015 |
20150045424 | COMPOSITION USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES - It is described the use of L-carnitine and/or an alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes. | 02-12-2015 |
20150051276 | FEEDING DETERRENCE IN AGRICULTURAL PESTS SUCH AS HEMIPTERA, LEPIDOPTERA AND COLEOPTERA - Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils. Feeding deterrence is obtained by contact of the insects with at least one of the compounds of the structure (I) wherein R is —OH, ═O, —OC(O)R | 02-19-2015 |
20150065567 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS - Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis. | 03-05-2015 |
20150080463 | METHODS FOR PREDICTING CARDIOVASCULAR EVENTS AND MONITORING TREATMENT USING PCSK9 - Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious. | 03-19-2015 |
20150133540 | CONTROL AND REPELLENCY OF MOSQUITOES - Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) | 05-14-2015 |
20150148410 | IDENTIFICATION OF SPECIFIC APOLIPOPROTEIN EPITOPES ON CIRCULATING ATHEROGENIC LOW-DENSITY LIPOPROTEIN - An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those. | 05-28-2015 |
20150148411 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF DISORDERS RELATED TO ALTERATIONS OF MYH9 - Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer. | 05-28-2015 |
20150320903 | Biocompatible Phase Invertable Proteinaceous Compositions And Methods For Making And Using The Same - Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. | 11-12-2015 |
20150322032 | Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia - The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease. | 11-12-2015 |
20150366797 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS - The invention includes methods and compositions for treating mastitis in a subject. The method includes the step of administering, by intramammary delivery, a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the mammary gland of the subject. | 12-24-2015 |
20160000748 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS - The invention is a method and composition for treating a topical microbial infection in a subject. The method includes the step of administering a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the subject. | 01-07-2016 |
20160038391 | METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN - Embodiments of the present invention are directed to methods and articles of manufacture to treat skin to improve and/or increase hydration, pliability, and thickness for improved texture, feel and appearance. Embodiments feature applying an effective amount of an acetylation agent to natural dermal collagen under reaction conditions to react the natural dermal collagen with the acetylation agent to form a modified collagen. The modified collagen has a higher net charge and higher net charge density than natural dermal collagen. The modified collagen improves or increases one or more skin characteristics consisting of hydration, pliability and thickness. | 02-11-2016 |
20160045604 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines. | 02-18-2016 |
20160136130 | Oral Ultraviolet Resistance Enhancer - To provide an ultraviolet resistance enhancer capable of enhancing resistance of the skin to ultraviolet rays by oral ingestion, thereby reducing or suppressing skin damages caused by exposure to ultraviolet rays. An oral ultraviolet resistance enhancer comprising glucono-δ-lactone as an active ingredient. | 05-19-2016 |
20160158194 | Methods and Treatments for the Learning and Memory Deficits Associated with Noonan Syndrome - Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome. | 06-09-2016 |
20160374986 | PPARs AGONIST ACTIVITY ENHANCING DRUG - A lifestyle disease improving drug is disclosed that enhances PPARα, δ and γ agonist activities that includes a compound having the lactone structure in accordance with the chemical formula 6-alkyl-5,6-dihydro-2H-pyran-2-one, the alkyl containing 4, 5, or 6 carbons. Methods for enhancing PPARα, γ and δ agonist activities in vertebrates or medically treating a vertebrate are disclosed. The methods include providing a composition of an active ingredient, the lifestyle disease improving drug, in a biologically acceptable medium and administering an effective amount of the composition to a vertebrate. | 12-29-2016 |